FDA Approves Aloxi for Chemotherapy-Induced Nausea and Vomiting (CINV)
Aloxi (palonosetron) is a 5-HT3 receptor antagonist indicated for the prevention of delayed CINV caused by moderately emetogenic cancer chemotherapy.Posted: July 2003
Related Articles:
- FDA Approves Aloxi (palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting - August 25, 2008
- FDA Approves Aloxi (palonosetron HCl) Injection for Prevention of Postoperative Nausea and Vomiting - March 3, 2008
- MGI Pharma and Helsinn Announce Aloxi sNDA Approval Allowing for Repeated Dosing for Cancer Patients Receiving Multiple Day Chemotherapy Regimens - September 4, 2007
- MGI Pharma and Helsinn Announce Aloxi sNDA for PONV Accepted for Review By U.S. FDA - July 9, 2007
